** Morgan Stanley downgrades rating on telehealth firm Hims and Hers HIMS.N to "equal weight" from "overweight"
** HIMS shares down marginally at $60.35 premarket
** "While HIMS checks a lot of boxes we evaluate for an investment thesis ... meaningful outperformance in the stock raises the bar near term" - brokerage
** Stock has been trading at record highs in recent days and has risen 150% so far in 2025
** MS points to investor optimism over the company's business of selling compounded versions of GLP-1 weight-loss injections, such as Novo Nordisk's NOVOb.CO Wegovy, as driving the recent gains in stock
** MS also raised PT to $60 from $42
** 7 of 16 brokerages rate the stock "buy" or higher, 7 "hold" and 2 "sell" or lower; their median PT is $26 - LSEG data
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.